Other Clinical Trial - Predictive Value of PRECISE DAPT Score in STEMI

Status Not yet recruiting

Clinical Trial Summary

To investigate the predictive value of PRECISE DAPT score in relation to coronary slow flow & other short term major adverse cardiovascular events (MACE) post PPCI .

Clinical Trial Description

Coronary artery disease (CAD) is the leading cause of death around the world and more than 4 million people die every year due to CAD in Europe.[1] The incidence of ST elevation myocardial infarction (STEMI) appears to be declining; however, it is still an important issue in cardiovascular medicine.[2] Initial risk assessment is important for STEMI to estimate adverse cardiovascular outcomes. Previous studies demonstrated that increased age, advanced Killip class, heart rate, arterial hypotension, increased serum creatinine, white blood cell counts, and hemoglobin levels were predictors of in-hospital and early mortality in patients with STEMI treated with primary percutaneous coronary intervention (PPCI).[3,4 ]Therefore, risk scores including the aforementioned parameters were developed to estimate mortality in patients with STEMI.

No-reflow is still a challenging major issue in the management of the patients with STEMI undergoing primary PCI. It is defined as inadequate myocardial perfusionthrough a given segment of the coronary circulation without angiographic evidence of mechanical vessel obstructionas [5] Angiographic no-reflow defined as less than Thrombolysis In Myocardial Infarction (TIMI) 3 flow [6] and angiographic success was defined as TIMI Grade 3 Flow .

PRECISE-DAPT score includes age, creatinine clearance, white blood cell counts, hemoglobin levels, and prior spontaneous bleeding [7]. All these factors have a close relationship with coronary artery disease (CAD) and complications [8-10]. Therefore, in this study, we aimed to evaluate the association of admission PRECISE-DAPT score with the development of slow flow & bleeding & othershort term cardiovascular complications that develop in patients with STEMI treated with primary PCI. ;

Study Design

Related Conditions & MeSH terms

Infarction
Myocardial Infarction
ST Elevation Myocardial Infarction
ST-segment Elevation Myocardial Infarction (STEMI)

Clinical Trial Details

NCT number	NCT04549766
Study type	Observational
Source	Assiut University
Contact	Madonna Atef, Resident
Phone	01012767967
Email	donna.atef555@gmail.com
Status	Not yet recruiting
Phase
Start date	September 2020
Completion date	October 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04962178` - Evaluate Early Invasive Strategy for Patients With STEMI Presenting 24-48 Hours From Symptom Onset	N/A
Not yet recruiting	`NCT05511831` - The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI	Phase 4
Completed	`NCT05649696` - Prolonged Clinical Follow-up of OPTIMA-5	Phase 4
Recruiting	`NCT05506449` - The RECOVER IV Trial	N/A
Completed	`NCT01144819` - Platelet Inhibition in the Acute Phase of STEMI	N/A
Recruiting	`NCT03539133` - Systemic Organ Communication in STEMI
Completed	`NCT01642667` - Pharmacoinvasive Therapy With Prourokinase	Phase 2/Phase 3
Completed	`NCT04131816` - HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program	N/A
Recruiting	`NCT03768453` - EARLY-MYO-CMR Registry
Completed	`NCT04942977` - Rehabilitation After Acute Coronary Syndrome: a New Telemonitoring Strategy	N/A
Recruiting	`NCT04912518` - Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction	N/A
Completed	`NCT04996901` - The Chinese STEMI PPCI Registry (CSPR)
Recruiting	`NCT05892042` - Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction	N/A
Completed	`NCT02197117` - Effect of Remote Ischemic Conditioning in Heart Attack Patients	N/A
Completed	`NCT02733341` - The Effect of IV Cangrelor and Oral Ticagrelor Study	Phase 4
Not yet recruiting	`NCT04110691` - Impact of Stent Length and Diameter on Patients Undergoing Primary PCI
Recruiting	`NCT05510661` - Use of Export in Primary Percutaneous Coronary Intervention	N/A
Recruiting	`NCT05709626` - PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction	Phase 4
Recruiting	`NCT05046483` - Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
Active, not recruiting	`NCT04828681` - Angio-IMR and Cardiac MR-derived MVO in STEMI Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Predictive Value of PRECISE DAPT Score in STEMI Patients After Primary PCI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms